Search clinical trials for: long acting injectable

Total 71233 results

Georgetown University
Johns Hopkins Bloomberg School of Public Health; United States Agency for International... and other collaborators

Recruiting

PathToScale: An Implementation Evaluation

Oral Pre-exposure Prophylaxis (PrEP) | Long-acting Injectable Cabotegravir for PrEP

Malawi
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
Midway Specialty Care Center

Recruiting

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Hiv

United States
Beth Israel Deaconess Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (Tshireletso)

Breast Feeding | Pre-Exposure Prophylaxis (PrEP)

United States, Botswana
Oregon Health and Science University
ViiV Healthcare

Recruiting

Oregon PrEP at Home Study (OR-PrEP@Home)

HIV/AIDS

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, Italy, Spain, Argentina, Germany, France, Canada, Chile, Puerto Rico
Kelley-Ross & Associates, Inc.

Not yet recruiting

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. (IDCaPP)

HIV Infections

United States
Pontificia Universidad Catolica de Chile
ViiV Healthcare

Not yet recruiting

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (CABO-LA)

Quality of Life | Patient Satisfaction | Patient Preference | Acceptability of Health Care

Chile
City University of New York
New York City Department of Health and Mental Hygiene

Recruiting

Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI) (APPLI)

Hiv

United States
Cali Pharmaceuticals LLC

Recruiting

CPL-01 in the Management of Postoperative Pain After Bunionectomy

Bunion

United States
Alexis Roth
University of Miami; Beth Israel Deaconess Medical Center; University of Michigan and other collaborators

Recruiting

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

HIV Infections | Opioid Use | Trauma, Psychological

United States
University of Liverpool
Obafemi Awolowo University Teaching Hospital; Federal Medical Centre, Makurdi; Federal Neuropsychiatric Hospital, Yaba and other collaborators

Recruiting

Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum (LAMP)

Schizophrenia | Pregnancy | Mania | Psychosis | Breastfeeding | Antipsychotic Agents | Drug Exposure in Utero | Drug Exposure Via Breast Milk

Nigeria
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

HIV-1-infection

United States, Brazil, South Africa, Uganda, Botswana, Thailand
ViiV Healthcare

Recruiting

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (EBONI)

HIV Infections

United States
Rovi Pharmaceuticals Laboratories

Recruiting

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse (RESHAPE)

Schizophrenia

Germany
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
Hôpital Européen Marseille

Recruiting

Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy (LAMIVIH)

HIV Infections

France
Mazonson & Santas Inc.
Icahn School of Medicine at Mount Sinai; ViiV Healthcare; AIDS Healthcare Foundation and other collaborators

Recruiting

Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables (ADHOC-LA)

HIV

United States
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID); Indiana University and other collaborators

Recruiting

Kuwa Free! - Live Free!

HIV Infections | Contraception | Drug-drug Interaction

Kenya
Otsuka Canada Pharmaceutical Inc.
Lundbeck Canada Inc.

Recruiting

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE) (INITIATE)

Schizophrenia | Schizo Affective Disorder | Bipolar I Disorder

Canada
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Puerto Rico, Botswana, South Africa, Uganda
Janssen-Cilag International NV

Active, not recruiting

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
Janssen Pharmaceuticals

Completed

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

HIV Infections

Germany, Netherlands, France, Belgium, Spain
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare

Active, not recruiting

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PILLAR)

HIV Infections

United States
ViiV Healthcare
Janssen Research and Development

Active, not recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M)

HIV Infections

United States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
Tonghua Dongbao Pharmaceutical Co.,Ltd

Completed

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Diabetes

China
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
University of Palermo

Completed

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Diabetes Mellitus, Type 2

Italy
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa
University of California, San Francisco
Texas A&M University; ViiV Healthcare; Auburn University; Nova Southeastern University

Completed

Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

Hiv

United States
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

HIV Infections

United States, Puerto Rico
ViiV Healthcare

Completed

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HIV Infections

Zimbabwe, South Africa, Botswana, Kenya, Malawi, Uganda, Swaziland
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Schizophrenia

United States
Alkermes, Inc.

Completed

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Schizophrenia

United States
Intra-Cellular Therapies, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Schizophrenia
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Schizophrenia (Recent-onset)

United States
Martha Sajatovic
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Bipolar Disorder | Medication Adherence | Medication Non Adherence

United States
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone.

Schizophrenia

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics (MAESTRO)

Schizophrenia | Antipsychotics | Long-Acting Injection | LAI | Aripiprazole

Korea, Republic of
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone

Schizophrenia

United States

Search clinical trials for: long acting injectable

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations